Amantadine improves gait in PD patients with STN stimulation
- Autores
- Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; Moro, Elena
- Año de publicación
- 2013
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.
Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong Kong
Fil: Kukkle, Prashanth L.. University of Toronto; Canadá
Fil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lim, Shen Yang. University of Malaya; Malasia
Fil: Poon, Yu Yan. University of Toronto; Canadá
Fil: Moro, Elena. Universite Joseph Fourier; Francia - Materia
-
Gait
Speech
Deep Brain Stimulation
Balance
Amantadine
Parkinson'S Disease - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/23878
Ver los metadatos del registro completo
id |
CONICETDig_ab237343a4b1cce95cbb3f564146a6bf |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/23878 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Amantadine improves gait in PD patients with STN stimulationChan, Hiu FaiKukkle, Prashanth L.Merello, Marcelo JorgeLim, Shen YangPoon, Yu YanMoro, ElenaGaitSpeechDeep Brain StimulationBalanceAmantadineParkinson'S Diseasehttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong KongFil: Kukkle, Prashanth L.. University of Toronto; CanadáFil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lim, Shen Yang. University of Malaya; MalasiaFil: Poon, Yu Yan. University of Toronto; CanadáFil: Moro, Elena. Universite Joseph Fourier; FranciaElsevier2013-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/23878Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-3191353-8020CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1353802012004385info:eu-repo/semantics/altIdentifier/doi/10.1016/j.parkreldis.2012.11.005info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:40:14Zoai:ri.conicet.gov.ar:11336/23878instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:40:14.274CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Amantadine improves gait in PD patients with STN stimulation |
title |
Amantadine improves gait in PD patients with STN stimulation |
spellingShingle |
Amantadine improves gait in PD patients with STN stimulation Chan, Hiu Fai Gait Speech Deep Brain Stimulation Balance Amantadine Parkinson'S Disease |
title_short |
Amantadine improves gait in PD patients with STN stimulation |
title_full |
Amantadine improves gait in PD patients with STN stimulation |
title_fullStr |
Amantadine improves gait in PD patients with STN stimulation |
title_full_unstemmed |
Amantadine improves gait in PD patients with STN stimulation |
title_sort |
Amantadine improves gait in PD patients with STN stimulation |
dc.creator.none.fl_str_mv |
Chan, Hiu Fai Kukkle, Prashanth L. Merello, Marcelo Jorge Lim, Shen Yang Poon, Yu Yan Moro, Elena |
author |
Chan, Hiu Fai |
author_facet |
Chan, Hiu Fai Kukkle, Prashanth L. Merello, Marcelo Jorge Lim, Shen Yang Poon, Yu Yan Moro, Elena |
author_role |
author |
author2 |
Kukkle, Prashanth L. Merello, Marcelo Jorge Lim, Shen Yang Poon, Yu Yan Moro, Elena |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
Gait Speech Deep Brain Stimulation Balance Amantadine Parkinson'S Disease |
topic |
Gait Speech Deep Brain Stimulation Balance Amantadine Parkinson'S Disease |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS. Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong Kong Fil: Kukkle, Prashanth L.. University of Toronto; Canadá Fil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Lim, Shen Yang. University of Malaya; Malasia Fil: Poon, Yu Yan. University of Toronto; Canadá Fil: Moro, Elena. Universite Joseph Fourier; Francia |
description |
In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/23878 Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-319 1353-8020 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/23878 |
identifier_str_mv |
Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-319 1353-8020 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1353802012004385 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.parkreldis.2012.11.005 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614429507846144 |
score |
13.070432 |